Cargando…

EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS

OBJECTIVE: Infection with Epstein-Barr virus (EBV) has been associated with clinical activity and risk of developing MS. The purpose of this study is to investigate the impact of glatiramer acetate (GA) therapy on EBV-specific immune responses and disease course. METHODS: We characterized EBV-specif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerrera, Gisella, Ruggieri, Serena, Picozza, Mario, Piras, Eleonora, Gargano, Francesca, Placido, Roberta, Gasperini, Claudio, Salvetti, Marco, Buscarinu, Maria Chiara, Battistini, Luca, Borsellino, Giovanna, Angelini, Daniela F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455312/ https://www.ncbi.nlm.nih.gov/pubmed/32817203 http://dx.doi.org/10.1212/NXI.0000000000000876

Ejemplares similares

Proinflammatory mucosal-associated invariant CD8+ T cells react to gut flora yeasts and infiltrate multiple sclerosis brain
por: Gargano, Francesca, et al.
Publicado: (2022)

One, No One, and One Hundred Thousand: T Regulatory Cells' Multiple Identities in Neuroimmunity
por: Sambucci, Manolo, et al.
Publicado: (2019)

FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis
por: Sambucci, Manolo, et al.
Publicado: (2018)

Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis
por: Angelini, Daniela F., et al.
Publicado: (2013)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
por: Häusler, Darius, et al.
Publicado: (2020)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

BDNF and Pro-BDNF in Amyotrophic Lateral Sclerosis: A New Perspective for Biomarkers of Neurodegeneration
por: Riolo, Giulia, et al.
Publicado: (2022)

Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk
por: Strafella, Claudia, et al.
Publicado: (2021)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Primary and Recall Immune Responses to SARS-CoV-2 in Breakthrough Infection
por: D’Orso, Silvia, et al.
Publicado: (2023)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017)

Process signatures in glatiramer acetate synthesis: structural and functional relationships
por: Campos-García, Víctor R., et al.
Publicado: (2017)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
por: Vlahova, Lyubomira, et al.
Publicado: (2021)

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients
por: Lee, Andrew, et al.
Publicado: (2017)

Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals
por: De Marco, Lorenzo, et al.
Publicado: (2022)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
por: Towfic, Fadi, et al.
Publicado: (2014)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate
por: Moore, Spencer, et al.
Publicado: (2014)

Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
por: Davis, Mat D., et al.
Publicado: (2017)

Glatiramer acetate treatment negatively regulates type I interferon signaling
por: Molnarfi, Nicolas, et al.
Publicado: (2015)

Glatiramer acetate does not protect from acute ischemic stroke in mice
por: Kraft, Peter, et al.
Publicado: (2014)

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis
por: Kuerten, Stefanie, et al.
Publicado: (2018)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2020)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
por: Mirabella, Massimiliano, et al.
Publicado: (2022)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
por: Koc, Ümmügülsüm, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rom3l80uaj1ob7vn8887dv1ol